CEO of Wuhan General Group Provides Key Updates and Outlook

CEO of Wuhan General Group Provides Key Updates and Outlook

Jeff Robinson, CEO of Wuhan, Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com

 Source: Wuhan General Group, Inc.

AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by SmallCapVoice.com, Inc. and Wuhan General Group, Inc. (OTC PINK: WUHN), please note that additional content and quotations have become available. The corrected release follows:

SmallCapVoice.com, Inc. (SCV) and Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), announced today that a new audio interview with the Company is now available.

The interview featuring an overview of WUHN’s current news and moves can be heard at https://www.smallcapvoice.com/tag/wuhn/.

Jeff Robinson, CEO of Wuhan, called in to SmallCapVoice.com to go over the business model and markets that his Company operates in. Wuhan is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical cannabidiol (CBD) space, as well as the promising psilocybin medical health sector.

The Company’s subsidiary MJ MedTech is a cosmetics and food for special medical purposes (FSMP) company with leading alternative plant-based cannabinoids and psilocybin medical research, formulation and delivery system divisions. Cannabinoids and mushroom-based formulations are under the Dr. AnnaRx™ and Medspresso™ brands.

The Company’s cannabinoids research and development division is focused on new treatments to help patients who suffer from chronic and inflammatory diseases: inflammatory bowel syndrome, arthritis, chronic respiratory diseases, migraine, sleeping disorders, cancer and diabetes.

In addition, its division M2Bio is researching and developing indications for psilocybin new therapies that will help patients diagnosed with mental health disorders, Alzheimer’s, Parkinson’s, major depressive disorder, drug and alcohol addiction, and cardiovascular diseases.

As well, Wuhan has been researching multiple medicinal mushroom types in order to formulate its upcoming range of mushroom-infused cosmetics, coffee, and teas for commercialization in late 2020 within its Dr. AnnaRx™ and Medspresso™ brands.

In the interview Robinson stated, “We are one of only a handful of companies in the world working with psilocybin and conducting clinical trials. On the CBD side, once the lockdown ends in South Africa, our products will be on store shelves. That would be the products in the Dr. AnnaRx™ and Medspresso™ brands. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.

“The company name change, updated financials and fully reporting status, key employee new hires, strategic new partnerships, research findings and new clinical initiatives – just a few items soon to be shared. We are extremely excited!”

Wuhan General Group, Inc. is a client of StockVest. StockVest’s team of top Influencers introduces publicly traded companies to a wide audience of investors from around the globe helping public companies attain maximum market awareness resulting in increased trading volume, a broadened shareholder base and increased share valuations.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly  owned  subsidiary  MJ  MedTech  is  a  cosmetics and food  for  special  medical  purposes  (FSMP)  company  with  leading  alternative  plant-based cannabinoids and  psilocybin  medical  research,  formulation  and  delivery  system  divisions. Cannabinoids and mushroom-based formulations are under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its established division, M2Bio is researching  and  developing  indications  for  psilocybin new therapies that will help patients diagnosed with mental  health  disorders, Alzheimer’s, Parkinson’s, major depressive disorder, drug and alcohol addiction, cardiovascular diseases and PTSD. Our mission is to advance botanical-based medicine to the forefront by deploying best- practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Wuhan General Group, Inc.

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at;

Facebook: https://www.facebook.com/SmallCapVoice/  

Twitter: https://twitter.com/smallcapvoice   

Instagram: https://www.instagram.com/smallcapvoice/

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements. For further information contact:

Public Relations

E-mail: info@wuhn.org

For SmallCapVoice.com:

Stuart T. Smith

512-267-2430

info@smallcapvoice.com

Source: SmallCapVoice.com

Next PostRead more articles